Zoom In on Dementia & Alzheimer's Episodes
On July 2, 2024, the U.S. Food and Drug Administration approved Kisunla (donanemab), a new Alzheimer’s medication shown to slow the progression of the disease. Join our conversation with Dr. Paul Aisen as he details how the drug works, for whom, side effects, what it costs, whether it’s covered by insurance, and how it compares with other new Alzheimer’s medicines.
If you learn about your specific genetic makeup early enough – before symptoms of memory loss begin – could you benefit from this knowledge? Would you be eligible for specific types of treatment? Join us as we explore the importance of understanding your genetic risk for Alzheimer’s and related dementias.
Are you between 18-95 years old and interested in brain health? Learn from leading scientists about two research opportunities that do NOT involve taking medications: the Emory Healthy Aging Study and the NeuroQuest Study.
This year, the Food and Drug Administration approved an artificial intelligence (AI) tool called BrainSee to predict the likelihood of Alzheimer’s progression using brain scans. Are AI programs the next frontier in forecasting, understanding, and managing Alzheimer’s? Dr. Timothy Hohman gives us the scoop on all things AI and dementia.
Distinguished Alzheimer’s expert Dr. Gil Rabinovici explains how early-onset Alzheimer’s is recognized, diagnosed, and treated and what separates it from the most common form of the disease.
International brain health expert Dr. Laura Baker helps to decipher the best evidence-based lifestyle strategies for protecting your brain as you age.
Listen to world-renowned Alzheimer’s expert Dr. Marwan Sabbagh as he guides us through the complex stages and progression of Alzheimer’s and helps us understand the resources available at each stage.
In 2023, there were 184 trials assessing 143 drugs for the treatment of Alzheimer's disease (AD) and Mild Cognitive Impairment, with more than 60,000 participants required to populate those registered trials at 5684 sites. What is happening in 2024? Listen to Dr. Jeffrey Cummings for the insider’s overview.
Three new drugs for Alzheimer’s disease have been approved, and pharmaceutical companies are currently testing 141 Alzheimer’s drugs in 178 clinical trials. World-renowned expert Dr. Reisa Sperling discusses what might be coming through the treatment pipeline for dementias within the next three years.
Join Dr. Richard S. Isaacson as he shares insights on how preventative lifestyle changes and individualized care can meaningfully reduce your dementia risk and benefit your overall health.
